Amedisys, Inc. Drops from S&P 400 Index

Amedisys, a healthcare service company, has dropped from the S&P 400 index. The company provides home-based care and support services, including home health, hospice, and high acuity care. Its home health segment has 346 care centers in 34 states, while its hospice care provides comfort and support for patients with terminal illnesses. The high acuity care segment delivers inpatient hospital and skilled nursing facility care to patients in their homes.

Amedisys Inc. (NASDAQ: AMED) has been removed from the S&P MidCap 400 index, effective August 19, 2025. This move comes after the completion of UnitedHealth Group's acquisition of Amedisys, which was announced earlier this year. The acquisition, valued at $3.3 billion, marks a significant expansion of UnitedHealth's home health capabilities, following a two-year battle with antitrust regulators [1].

UnitedHealth Group, a Minnesota-based healthcare giant, had initially planned to acquire Amedisys in 2023. However, the deal faced legal challenges from the U.S. Department of Justice (DOJ) due to concerns about competition in the home health and hospice services market. The parties eventually reached a settlement agreement on August 7, requiring Amedisys to divest 164 home health and hospice facilities to clear the way for the merger [2].

The divestment included 152 home health, 11 hospice, and 1 palliative care locations in local markets across 19 states. This settlement package was deemed significantly larger than the previously offered divestment package by the merging parties [2].

Amedisys, which provides home-based care and support services including home health, hospice, and high acuity care, had 346 care centers in 34 states and served more than 465,000 patients annually across 38 states and Washington, D.C. [1].

The acquisition of Amedisys by UnitedHealth Group is expected to have a modest impact on UnitedHealth's earnings, but it will bolster the company's vertical integration strategy. UnitedHealth already owns LHC Group, another home health and hospice care provider, which it acquired for $5.4 billion in 2023 [1].

The removal of Amedisys from the S&P MidCap 400 index follows a strong financial performance by Twilio Inc. (NYSE: TWLO), which will replace Amedisys in the index. Twilio's inclusion in the index reflects its robust financial performance and strategic innovations, including AI-driven communications platforms [3].

References:
[1] https://www.ainvest.com/news/twilio-replace-amedisys-midcap-400-2508/
[2] https://www.healthcaredive.com/news/unitedhealth-amedisys-deal-closes-doj/757742/
[3] https://www.jdsupra.com/legalnews/doj-settles-challenge-to-unitedhealth-2324858/